152 related articles for article (PubMed ID: 33145728)
1. Molecular subtypes of triple-negative breast cancer: understanding of subtype categories and clinical implication.
Lee YM; Oh MH; Go JH; Han K; Choi SY
Genes Genomics; 2020 Dec; 42(12):1381-1387. PubMed ID: 33145728
[TBL] [Abstract][Full Text] [Related]
2. Subtyping of triple-negative breast cancers: its prognostication and implications in diagnosis of breast origin.
Hu H; Tong K; Tsang JY; Ko CW; Tam F; Loong TC; Tse GM
ESMO Open; 2024 Apr; 9(4):102993. PubMed ID: 38613910
[TBL] [Abstract][Full Text] [Related]
3. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
Bareche Y; Venet D; Ignatiadis M; Aftimos P; Piccart M; Rothe F; Sotiriou C
Ann Oncol; 2018 Apr; 29(4):895-902. PubMed ID: 29365031
[TBL] [Abstract][Full Text] [Related]
4. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
Le Du F; Eckhardt BL; Lim B; Litton JK; Moulder S; Meric-Bernstam F; Gonzalez-Angulo AM; Ueno NT
Oncotarget; 2015 May; 6(15):12890-908. PubMed ID: 25973541
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes.
Basho RK; Zhao L; White JB; Huo L; Bassett RL; Mittendorf EA; Thompson A; Litton JK; Ueno N; Arun B; Lim B; Valero V; Tripathy D; Zhang J; Adrada BE; Santiago L; Ravenberg E; Seth S; Yam C; Moulder SL; Damodaran S
JCO Precis Oncol; 2024 Mar; 8():e2300124. PubMed ID: 38484209
[TBL] [Abstract][Full Text] [Related]
6. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes.
Lehmann BD; Pietenpol JA
J Pathol; 2014 Jan; 232(2):142-50. PubMed ID: 24114677
[TBL] [Abstract][Full Text] [Related]
7. A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics.
Quist J; Mirza H; Cheang MCU; Telli ML; O'Shaughnessy JA; Lord CJ; Tutt ANJ; Grigoriadis A
Mol Cancer Ther; 2019 Jan; 18(1):204-212. PubMed ID: 30305342
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity and transcriptional drivers of triple-negative breast cancer.
Jovanović B; Temko D; Stevens LE; Seehawer M; Fassl A; Murphy K; Anand J; Garza K; Gulvady A; Qiu X; Harper NW; Daniels VW; Xiao-Yun H; Ge JY; Alečković M; Pyrdol J; Hinohara K; Egri SB; Papanastasiou M; Vadhi R; Font-Tello A; Witwicki R; Peluffo G; Trinh A; Shu S; Diciaccio B; Ekram MB; Subedee A; Herbert ZT; Wucherpfennig KW; Letai AG; Jaffe JD; Sicinski P; Brown M; Dillon D; Long HW; Michor F; Polyak K
Cell Rep; 2023 Dec; 42(12):113564. PubMed ID: 38100350
[TBL] [Abstract][Full Text] [Related]
9. Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype.
Jézéquel P; Lasla H; Gouraud W; Basseville A; Michel B; Frenel JS; Juin PP; Ben Azzouz F; Campone M
Breast Cancer; 2024 May; ():. PubMed ID: 38777987
[TBL] [Abstract][Full Text] [Related]
10. Triple Negative Breast Cancers: An Obsolete Entity?
Keskinkılıc M; Gökmen-Polar Y; Badve SS
Clin Breast Cancer; 2024 Jan; 24(1):1-6. PubMed ID: 38016912
[TBL] [Abstract][Full Text] [Related]
11. The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification.
Weng L; Zhou J; Guo S; Xu N; Ma R
Cancer Cell Int; 2024 Mar; 24(1):120. PubMed ID: 38555429
[TBL] [Abstract][Full Text] [Related]
12. Enhancing therapeutic efficacy in luminal androgen receptor triple-negative breast cancer: exploring chidamide and enzalutamide as a promising combination strategy.
Zhao YX; Wang H; Zhang SW; Zhang WX; Jiang YZ; Shao ZM
Cancer Cell Int; 2024 Apr; 24(1):131. PubMed ID: 38594722
[TBL] [Abstract][Full Text] [Related]
13. Modulatory Role of microRNAs in Triple Negative Breast Cancer with Basal-Like Phenotype.
Angius A; Cossu-Rocca P; Arru C; Muroni MR; Rallo V; Carru C; Uva P; Pira G; Orrù S; De Miglio MR
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33171872
[TBL] [Abstract][Full Text] [Related]
14. Community cohesion looseness in gene networks reveals individualized drug targets and resistance.
Wang S; Lee D
Brief Bioinform; 2024 Mar; 25(3):. PubMed ID: 38622359
[TBL] [Abstract][Full Text] [Related]
15. Precision medicine for metastatic TNBC: the FUTURE is now.
Foldi J; Geyer CE
Cell Res; 2023 Jul; 33(7):491-492. PubMed ID: 37156878
[No Abstract] [Full Text] [Related]
16. Anti-androgen therapy in triple-negative breast cancer.
Barton VN; Gordon MA; Richer JK; Elias A
Ther Adv Med Oncol; 2016 Jul; 8(4):305-8. PubMed ID: 27482289
[No Abstract] [Full Text] [Related]
17. Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer.
Mediratta K; El-Sahli S; D'Costa V; Wang L
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33256070
[TBL] [Abstract][Full Text] [Related]
18. Triple‑negative breast cancer therapy: Current and future perspectives (Review).
Won KA; Spruck C
Int J Oncol; 2020 Dec; 57(6):1245-1261. PubMed ID: 33174058
[TBL] [Abstract][Full Text] [Related]
19. Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets.
Gong Y; Ji P; Yang YS; Xie S; Yu TJ; Xiao Y; Jin ML; Ma D; Guo LW; Pei YC; Chai WJ; Li DQ; Bai F; Bertucci F; Hu X; Jiang YZ; Shao ZM
Cell Metab; 2021 Jan; 33(1):51-64.e9. PubMed ID: 33181091
[TBL] [Abstract][Full Text] [Related]
20. Quadruple-negative breast cancer: novel implications for a new disease.
Bhattarai S; Saini G; Gogineni K; Aneja R
Breast Cancer Res; 2020 Nov; 22(1):127. PubMed ID: 33213491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
